NEOGENOMICS INCNEOEarnings & Financial Report
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
NEO Q4 2025 Key Financial Metrics
Revenue
$190.2M
Gross Profit
$83.3M
Operating Profit
$-13.4M
Net Profit
$-9.9M
Gross Margin
43.8%
Operating Margin
-7.1%
Net Margin
-5.2%
YoY Growth
10.6%
Financial Flow
NEOGENOMICS INC Q4 2025 Financial Summary
NEOGENOMICS INC reported revenue of $190.2M for Q4 2025, with a net profit of $-9.9M (-5.2% margin). Cost of goods sold was $106.8M, operating expenses totaled $96.8M.
Key Financial Metrics
| Total Revenue | $190.2M |
|---|---|
| Net Profit | $-9.9M |
| Gross Margin | 43.8% |
| Operating Margin | -7.1% |
| Report Period | Q4 2025 |
NEOGENOMICS INC Annual Revenue by Year
NEOGENOMICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $727.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $727.3M |
| 2024 | $660.6M |
| 2023 | $591.6M |
| 2022 | $509.7M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $156.2M | $164.5M | $167.8M | $172.0M | $168.0M | $181.3M | $187.8M | $190.2M |
| YoY Growth | 13.9% | 12.0% | 10.4% | 10.6% | 7.5% | 10.2% | 11.9% | 10.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.64B | $1.64B | $1.64B | $1.64B | $1.60B | $1.39B | $1.37B | $1.36B |
| Liabilities | $716.9M | $727.4M | $732.9M | $735.7M | $713.2M | $539.9M | $536.5M | $523.3M |
| Equity | $923.4M | $915.9M | $908.2M | $902.3M | $888.3M | $854.0M | $838.3M | $836.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-25.9M | $13.9M | $9.2M | $9.8M | $-25.3M | $20.3M | $8.9M | $1.3M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M